Claims for Patent: 7,807,680

Summary for Patent: 7,807,680

Title:	Controlled release sterile injectable aripiprazole formulation and method
Abstract:	A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
Inventor(s):	Kostanski; Janusz W. (Princeton, NJ), Matsuda; Takakuni (Tokushima, JP), Nerurkar; Manoj (Monmouth Junction, NJ), Naringrekar; Vijay H. (Princeton, NJ)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	10/968,482
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,807,680
Patent Claims:	1. A sterile freeze-dried controlled release aripiprazole formulation which comprises: (a) aripiprazole having a mean particle size of about 1 to 10 microns, and (b) one or more suspending agents, wherein said sterile freeze-dried controlled release aripiprazole formulation is in the form of a cake obtained by freeze-drying a homogeneous aqueous suspension comprising (a) and (b), and wherein upon reconstitution, which comprises adding water to said cake, a sterile injectable formulation is obtained which is a homogeneous suspension and which contains from about 0.1 to about 600 mg of aripiprazole per mL, and wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about two weeks from the date of administration. 2. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 1, wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about three weeks from the date of administration. 3. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 2, wherein said aripiprazole has a mean particle size of about 2.5 microns. 4. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 1, wherein said sterile freeze-dried controlled release aripiprazole formulation further comprises: (c) one or more bulking agents, and (d) one or more buffering agents. 5. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 4, wherein said sterile freeze-dried controlled release aripiprazole formulation further comprises: (e) a pH adjusting agent. 6. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 4, wherein said sterile freeze-dried controlled release aripiprazole formulation comprises: (a) aripiprazole having a mean particle size of about 1 to 10 microns, (b) carboxymethyl cellulose or its sodium salt, (c) mannitol, (d) sodium phosphate to adjust pH to about 7, and (e) optionally sodium hydroxide to adjust pH to about 7, wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about three weeks from the date of administration. 7. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 6, wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of about three to four weeks from the date of administration. 8. The sterile freeze-dried controlled release aripiprazole formulation as defined in any one of claims 1, 4 and 6, wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of three or four weeks from the date of administration. 9. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 6, wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of about four weeks from the date of administration. 10. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 1, wherein the aripiprazole is in the form of anhydrous crystals or in the form of a monohydrate. 11. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 10, wherein the aripiprazole is in the form of Aripiprazole Anhydride Crystals B or Aripiprazole Hydrate A. 12. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 4, wherein the aripiprazole is in the form of anhydrous crystals or in the form of a monohydrate. 13. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 12, wherein the aripiprazole is in the form of Aripiprazole Anhydride Crystals B or Aripiprazole Hydrate A. 14. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 6, wherein the aripiprazole is in the form of anhydrous crystals or in the form of a monohydrate. 15. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 14, wherein the aripiprazole is in the form of Aripiprazole Anhydride Crystals B or Aripiprazole Hydrate A. 16. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 4, wherein said sterile injectable formulation comprises: (a) aripiprazole having a mean particle size of about 1 to about 10 microns in an amount within the range from about 1 to about 40%, (b) suspending agent in an amount within the range from about 0.2 to about 10%, (c) bulking agent in an amount within the range from about 1 to about 10%, and (d) buffering agent in an amount within the range from about 0.02 to about 2% to adjust the pH of the sterile injectable formulation within the range from about 6 to about 7.5, wherein all of the above % are % by weight/volume based on the volume of the sterile injectable formulation. 17. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 4, wherein the suspending agent is selected from the group consisting of carboxymethylcellulose or its sodium-salt, hydroxypropyl cellulose, hydroxypropylethyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone; the bulking agent is selected from the group consisting of mannitol, sucrose, maltose, lactose, xylitol and sorbitol; and the buffering agent is selected from the group consisting of sodium phosphate, potassium phosphate and TRIS buffer. 18. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 6, wherein said sterile injectable formulation is selected from the group consisting of the following Formulations A, B and C: TABLE-US-00008 Formulation A Formulation B Formulation C aripiprazole having 100 mg 200 mg 400 mg a mean particle size of about 1 to 10 microns carboxymethyl 9 mg 9 mg 9 mg cellulose Mannitol 45 mg 45 mg 45 mg Sodium phosphate 0.8 mg 0.8 mg 0.8 mg Sodium qs to adjust qs to adjust qs to adjust Hydroxide pH to 7 pH to 7 pH to 7 water for qs to 1 mL qs to 1 mL qs to 1 mL injection. 19. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 4 or 6, wherein aripiprazole has a mean particle size of about 2.5 microns. 20. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 1, wherein upon reconstitution, which comprises adding water to said cake, a sterile injectable formulation is obtained which is a homogeneous suspension comprising aripiprazole in an amount of about 100 to about 400 mg/mL. 21. A sterile freeze-dried controlled release aripiprazole formulation comprising: (a) aripiprazole having a mean particle size of about 1 to 10 microns, wherein the aripiprazole is in the form of a monohydrate, and (b) one or more suspending agents, wherein said freeze-dried formulation is in the form of a cake obtained by freeze-drying a homogeneous aqueous suspension comprising (a) and (b), and wherein upon reconstitution, which comprises adding water to said cake, a sterile injectable formulation is obtained which is a homogeneous suspension and which contains from about 0.1 to about 600 mg of aripiprazole per mL, and wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about two weeks from the date of administration. 22. A sterile freeze-dried controlled release aripiprazole formulation which comprises: (a) aripiprazole having a mean particle size of about 1 to 10 microns, and (b) one or more suspending agents, wherein said freeze-dried formulation is in the form of a cake obtained by freeze-drying a homogeneous aqueous suspension comprising (a) and (b), and wherein upon reconstitution, which comprises adding water to said cake, a sterile injectable formulation is obtained which is a homogeneous suspension and which contains from about 0.1 to about 600 mg of aripiprazole per mL, and wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about one week from the date of administration. 23. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 22, wherein said sterile freeze-dried controlled release aripiprazole formulation further comprises: (c) one or more bulking agents, and (d) one or more buffering agents. 24. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 23, wherein said sterile freeze-dried controlled release aripiprazole formulation comprises: (a) aripiprazole having a mean particle size of about 1 to 10 microns, (b) carboxymethyl cellulose or its sodium salt, (c) mannitol, (d) sodium phosphate to adjust pH to about 7, and (e) optionally sodium hydroxide to adjust pH to about 7. 25. A method for preparing the sterile freeze-dried controlled release aripiprazole formulation as defined in claim 1 which comprises the steps of: (a) preparing sterile bulk aripiprazole having a desired particle size distribution, (b) preparing a sterile vehicle comprising one or more suspending agents for the sterile bulk aripiprazole, (c) combining said sterile aripiprazole and said sterile vehicle comprising one or more suspending agents to form a sterile primary suspension, (d) reducing the mean particle size of the aripiprazole in said sterile primary suspension to within the range from about 1 to about 10 microns to form a sterile final suspension containing from about 0.1 to about 600 mg of aripiprazole per mL, and (e) freeze-drying said sterile final suspension to form a cake. 26. The method as defined in claim 25, wherein the step of reducing the mean particle size of the aripiprazole in said sterile primary suspension is carried out employing wet milling. 27. The method as defined in claim 26, wherein the wet milling comprises wet ball milling. 28. The method as defined in claim 25, wherein said freeze drying step is carried out by cooling the sterile final suspension to about -40.degree. C. and drying the resulting cooled sterile final suspension at below about 0.degree. C., to form freeze dried aripiprazole in the form of its monohydrate. 29. The method as defined in claim 25, wherein the freeze drying step is carried out in three phases: (1) a freezing phase which includes cooling of the sterile final suspension at about -40.degree. C., (2) a primary drying phase which is performed at below about 0.degree. C., and (3) a secondary drying phase which is performed at above about 0.degree. C., to form aripiprazole in the form of anhydrous crystals. 30. The formulation as defined in claim 1, 4 or 6, wherein aripiprazole has a mean particle size of about 2 to 4 microns. 31. A sterile freeze-dried controlled release aripiprazole formulation as defined in claim 1 which is obtained by a process which comprises the steps of: (a) preparing sterile bulk aripiprazole having a desired particle size distribution, (b) preparing a sterile vehicle comprising one or more sterile suspending agents for the sterile bulk aripiprazole, (c) combining said sterile aripiprazole and said sterile vehicle comprising one or more sterile suspending agents to form a sterile primary suspension, (d) reducing the mean particle size of the aripiprazole in said sterile primary suspension to within the range from about 1 to about 10 microns to form a sterile final suspension containing from about 0.1 to about 600 mg of aripiprazole monohydrate per mL, and (e) freeze-drying said sterile final suspension to form a cake. 32. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 31, wherein the step of reducing the mean particle size of the aripiprazole in said sterile primary suspension is carried out employing wet milling. 33. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 32, wherein the wet milling comprises wet ball milling. 34. The sterile freeze-dried controlled release aripiprazole formulation of claim 31, wherein freeze-drying is carried out by cooling the homogeneous suspension of aripiprazole to about -40.degree. C. and drying the resulting cooled suspension at below 0.degree. C. under a vacuum, to form said cake. 35. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 16, wherein said sterile injectable formulation comprises: (a) aripiprazole having a mean particle size of about 1 to about 5 microns in an amount within the range from about 1 to about 40%, (b) suspending agent in an amount within the range from about 0.2 to about 10%, (c) bulking agent in an amount within the range from about 1 to about 10%, and (d) buffering agent in an amount within the range from about 0.02 to about 2% to adjust the pH of the sterile injectable formulation to about 6 to about 7.5, wherein all of the above % are % by weight/volume based on the volume of the sterile injectable formulation. 36. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 35, wherein said sterile injectable formulation comprises: (a) aripiprazole having a mean particle size of about 2.5 microns in an amount within the range from about 5 to about 20%, (b) suspending agent in an amount within the range from about 0.5 to about 5%, (c) bulking agent in an amount within the range from about 4 to about 5%, and (d) buffering agent in an amount within the range from about 0.03 to about 1% to adjust the pH of the sterile injectable formulation to about 6 to about 7.5, wherein all of the above % are % by weight/volume based on the volume of the sterile injectable formulation. 37. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 3, wherein the aripiprazole having a mean particle size of about 2.5 microns has a particle size distribution as follows: 95%<20 microns 90%<15 microns 50%<10 microns 10%<2 microns. 38. The sterile freeze-dried controlled release aripiprazole formulation as defined in claim 36, wherein the aripiprazole having a mean particle size of about 2.5 microns has a particle size distribution as follows: 95%<20 microns 90%<15 microns 50%<10 microns 10%<2 microns.